-
Product Insights
Post-Myocardial Infarction - Drugs In Development, 2024
Empower your strategies with our Post-Myocardial Infarction – Drugs In Development, 2024 report and make more profitable business decisions. After myocardial infarction (MI), patients are at a greater risk of heart failure. This happens when blood flow to the heart muscle is blocked. Long-term beta-blocker use after MI is associated with a reduced risk of reinfarction and death. Thus, it is critical to frequently re-evaluate beta-blocker eligibility among patients after MI with HF. The Post-Myocardial Infarction drugs in development market research...
-
Product Insights
Vascular Injury - Drugs In Development, 2024
Empower your strategies with our Vascular Injury – Drugs In Development, 2024 report and make more profitable business decisions. Vascular trauma refers to injury to a blood vessel—an artery, which carries blood to an extremity or an organ, or a vein, which returns blood to the heart. Vascular Surgeons categorize these injuries by the type of trauma that caused them: blunt or penetrating injury The Vascular Injury drugs in development market research report provide comprehensive information on the therapeutics under development...
-
Product Insights
Chronic Thromboembolic Pulmonary Hypertension - Drugs In Development, 2024
Empower your strategies with our Chronic Thromboembolic Pulmonary Hypertension – Drugs In Development, 2024 report and make more profitable business decisions. Chronic thromboembolic pulmonary hypertension (CTEPH) also called as Chronic pulmonary embolism, is a pulmonary vascular disease caused by chronic block of the major lung arteries. It is the major cause of chronic PH leading to right heart failure and death. The Chronic Thromboembolic Pulmonary Hypertension drugs in development market research report provide comprehensive information on the therapeutics under development for...
-
Sector Analysis
Resistant Hypertension (RH) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Resistant Hypertension (RH) Marketed and Pipeline Drugs Report Overview Resistant Hypertension (RH) refers to high blood pressure (BP) that is above the target level in a patient. This occurs even when they are taking three different classes of antihypertensive medications concurrently. These medication classes typically include diuretics, long-acting calcium channel blockers, and renin-angiotensin system blockers (ACEs or ARBs). The Resistant Hypertension (RH) marketed, and pipeline drugs research report includes an assessment of the disease epidemiology, leading marketed products with sales...
-
Sector Analysis
Peripheral Artery Disease (PAD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Peripheral Artery Disease Marketed and Pipeline Drugs Report Overview PAD is an atherosclerotic disease in which the formation of atherosclerotic plaque causes narrowing of the arteries and poor perfusion to the limbs. This can progress to arterial occlusion and chronic limb-threatening ischemia (CLTI). PAD can happen in any blood vessel, but it is more common in the legs than the arms. Key Mechanisms of Action (Marketed) · Receptor Agonist · Enzyme Inhibitor · Biological Factor Activator · Ligand Inhibitor · ...
-
Sector Analysis
Acute Ischemic Stroke (AIS) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Acute Ischemic Stroke Competitive Analysis Report Overview AIS is a medical emergency caused by decreased blood flow to the brain, which results in damage to brain cells. It occurs when a blood vessel in the brain is blocked by a clot or mass, impeding blood flow to brain cells. The primary cause of ischemic stroke is atherosclerosis, the accumulation of fatty deposits (plaque) on vessel walls. These deposits can cause two types of obstruction, including cerebral thrombosis and cerebral embolism. Key Mechanisms...
-
Product Insights
Peripheral Artery Occlusive Disease (PAOD) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Peripheral Artery Occlusive Disease (PAOD) Clinical Trials Overview The Peripheral Artery Occlusive Disease (PAOD) clinical trial report consists of 1328 trials. The report provides an overview of the Peripheral Artery Occlusive Disease (PAOD) clinical trial scenario. Our study also includes top-line data relating to the clinical trials on Peripheral Artery Occlusive Disease (PAOD), in this report. Our analysts have further provided an overview of trial numbers and their average enrolment in top countries conducted across the globe. Furthermore, our review...
-
Sector Analysis
Heart Failure Epidemiology Analysis and Forecast to 2032
Heart Failure Epidemiology Analysis Report Overview In the 7MM, there were 3,094,817 diagnosed incident cases of heart failure in 2022 and will grow at an AGR of more than 1% during 2022-2032. Heart failure (HF) is a condition characterized by the reduced ability of the heart to pump and/or fill with blood. It is a lifelong condition in which the heart muscle cannot pump enough blood to meet the body’s needs for blood and oxygen. HF is diagnosed through blood...
-
Sector Analysis
Atrial Fibrillation Epidemiology Analysis and Forecast to 2032
Atrial Fibrillation Market Report Overview In the 8MM, there were 14,457,906 total prevalent cases of Atrial Fibrillation in 2022. The cases are expected to achieve an AGR of more than 2% during the period 2022-2032. Atrial fibrillation (AF) is characterized by an irregular and often very rapid heart rhythm, or arrhythmia, that can lead to blood clots in the heart. This increases the risk of stroke, heart failure, and other cardiac complications. In AF patients, the normal beating in the...
-
Sector Analysis
Myocardial Infarction (MI) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Myocardial Infarction Marketed Drugs Overview Myocardial infarction (MI), colloquially known as “heart attack,” is caused by decreased or complete cessation of blood flow to a portion of the myocardium. In most cases, this occurs as a result of occlusive coronary atherosclerosis superimposed with a luminal thrombus. The following are some of the key highlights of the myocardial infarction market: In 2025, GlobalData estimates that the highest diagnosed prevalence of MI cases will be in India and China. In 2023, Mashhad...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.